SCHEMBL23945556

SCHEMBL23945556

C=Cc1cccc(C(C)C)c1N/C=C\C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 2/20 0.36
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GABRA1 P14867 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
FAAH O00519 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
GABRB1 P18505 1/20 0.34
PTGS1 P23219 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2C P28335 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24764000 0.86 LMNA (0.37) SOAT1LMNAKMT2ASMN1; SMN2GABRA1
SCHEMBL19188546 0.84 GABRA1 (0.43) SOAT1LMNAKMT2ASMN1; SMN2GABRA1
SCHEMBL13556567 0.78 KMT2A (0.46) SOAT1LMNAKMT2ASMN1; SMN2MEN1
SCHEMBL25973405 0.77 MAPK1 (0.43) SOAT1LMNAKMT2ASMN1; SMN2GABRA1
SCHEMBL23974687 0.77 MAPK1 (0.43) SOAT1LMNAKMT2ASMN1; SMN2GABRA1
SCHEMBL13257962 0.76 GABRA1 (0.46) SOAT1LMNAKMT2ASMN1; SMN2GABRA1
SCHEMBL13944066 0.75 CXCL8 (0.38) LMNAKMT2ASMN1; SMN2GABRA1GABRG2
SCHEMBL26215268 0.74 SMN1; SMN2 (0.40) SOAT1LMNAKMT2ASMN1; SMN2GABRA1
SCHEMBL13944069 0.73 LPAR1 (0.33) LMNAKMT2ASMN1; SMN2GABRA1GABRG2
SCHEMBL56243 0.72 GABRA1 (0.44) LMNAKMT2AGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 SOAT1 4125/4885LMNA 1656/4885KMT2A 445/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SOAT1 4125/4885LMNA 1656/4885KMT2A 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.